EICHOR
● Active Not Recruiting
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Condition: Lymphoma, Non-Hodgkin · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) \[Part A: Dose Escalation\] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs \[Part B: Dose Expansion\].
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (12)
| Austin Hospital | Heidelberg, Australia | — |
| The Alfred Hospital | Melbourne, Australia | — |
| Linear Clinical Research Ltd | Nedlands, Australia | — |
| Scientia Clinical Research | Randwick, Australia | — |
| Rigshospitalet | Copenhagen, Denmark | — |
| Odense University Hospital | Odense, Denmark | — |
| Hadassah Medical Center | Jerusalem, Israel | — |
| Sourasky (Ichilov) Medical Center | Tel Aviv, Israel | — |
| Hosp Univ Vall D Hebron | Barcelona, Spain | — |
| Hosp Univ Fund Jimenez Diaz | Madrid, Spain | — |
| Clinica Univ. de Navarra | Pamplona, Spain | — |
| Hosp Clinico Univ de Salamanca | Salamanca, Spain | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06139406